Synthesis of unsymmetrical c5-curcuminoids as potential anticancer agents

Letters in Drug Design and Discovery

Volumn 11, Issue 2, 2014, Pages 138-149

  Manohar, Sunny ^a   Thakur, Anuj ^a   Khan, Shabana I ^b   Sun, Guojing ^c   Ni, Nanting ^c   Wang, Binghe ^c   Rawat, Diwan S ^a  

^a UNIVERSITY OF DELHI   (India)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Anticancer activity; Antimalarial activity; C5 curcuminoids; Curcumin; HeLa cancer cell line; Plasmodium falciparum

Indexed keywords

1 (3,4 DIMETHOXYPHENYL) 5 [3 METHOXY 4 [2 (2 METHYL 1H IMIDAZOL 1 YL)ETHOXY]PHENYL]PENTA 1,4 DIEN 3 ONE; 1 (3,4 DIMETHOXYPHENYL) 5 [3 METHOXY 4 [2 (P TOLYLAMINO)ETHOXY]PHENYL]PENTA 1,4 DIEN 3 ONE; 1 (3,4 DIMETHOXYPHENYL) 5 [3 METHOXY 4 [2 (PHENYLAMINO)ETHOXY]PHENYL]PENTA 1,4 DIEN 3 ONE; 1 (3,4 DIMETHOXYPHENYL) 5 [3 METHOXY 4 [2 (PIPERIDIN 1 YL)ETHOXY]PHENYL]PENTA 1,4 DIEN 3 ONE; 1 (3,4 DIMETHOXYPHENYL) 5 [3 METHOXY 4 [2 (PYRROLIDIN 1 YL)ETHOXY]PHENYL]PENTA 1,4 DIEN 3 ONE; 1 (3,4 DIMETHOXYPHENYL) 5 [3 METHOXY 4 [2 [4 [(P TOLYLOXY)METHYL] 1H 1,2,3 TRIAZOL 1 YL]ETHOXY]PHENYL]PENTA 1,4 DIEN 3 ONE; 1 (3,4 DIMETHOXYPHENYL) 5 [3 METHOXY 4 [3 (2 METHYL 1H IMIDAZOL 1 YL)(PIPERIDIN 1 YL)PROPOXY]PHENYL]PENTA 1,4 DIEN 3 ONE; 1 (3,4 DIMETHOXYPHENYL) 5 [3 METHOXY 4 [3 (P TOLYLAMINO)PROPOXY]PHENYL]PENTA 1,4 DIEN 3 ONE; 1 (3,4 DIMETHOXYPHENYL) 5 [3 METHOXY 4 [3 (PHENYLAMINO)PROPOXY]PHENYL]PENTA 1,4 DIEN 3 ONE; 1 (3,4 DIMETHOXYPHENYL) 5 [3 METHOXY 4 [3 (PIPERIDIN 1 YL)PROPOXY]PHENYL]PENTA 1,4 DIEN 3 ONE; 1 (3,4 DIMETHOXYPHENYL) 5 [3 METHOXY 4 [3 (PYRROLIDIN 1 YL)PROPOXY]PHENYL]PENTA 1,4 DIEN 3 ONE; 1 (3,4 DIMETHOXYPHENYL) 5 [4 [2 (DIMETHYLAMINO)ETHOXY] 3 METHOXYPHENYL]PENTA 1,4 DIEN 3 ONE; 1 (3,4 DIMETHOXYPHENYL) 5 [4 [2 [4 (HYDROXYMETHYL) 1H 1,2,3 TRIAZOL 1 YL]ETHOXY] 3 METHOXYPHENYL]PENTA 1,4 DIEN 3 ONE; 1 (3,4 DIMETHOXYPHENYL) 5 [4 [3 (DIMETHYLAMINO)PROPOXY] 3 METHOXYPHENYL]PENTA 1,4 DIEN 3 ONE; 1 (3,4 DIMETHOXYPHENYL) 5 [4 [3 [4 (HYDROXYMETHYL) 1H 1,2,3 TRIAZOL 1 YL)PROPOXY] 3 METHOXYPHENYL]PENTA 1,4 DIEN 3 ONE; 1 [4 (2 AZIDOETHOXY) 3 METHOXYPHENYL] 5 (3,4 DIMETHOXYPHENYL)PENTA 1,4 DIEN 3 ONE; 1 [4 (2 BROMOETHOXY) 3 METHOXYPHENYL] 5 (3,4 DIMETHOXYPHENYL)PENTA 1,4 DIEN 3 ONE; 1 [4 (3 AZIDOPROPOXY) 3 METHOXYPHENYL] 5 (3,4 DIMETHOXYPHENYL)PENTA 1,4 DIEN 3 ONE; 1 [4 (3 BROMOPROPOXY) 3 METHOXYPHENYL] 5 (3,4 DIMETHOXYPHENYL)PENTA 1,4 DIEN 3 ONE; 1 [4 [2 [4 [(4 CHLOROPHENOXY)METHYL] 1H 1,2,3 TRIAZOL 1 YL]ETHOXY] 3 METHOXYPHENYL] 5 (3,4 DIMETHOXYPHENYL)PENTA 1,4 DIEN 3 ONE; 1 [4 [3 [4 [(4 CHLOROPHENOXY)METHYL] 1H 1,2,3 TRIAZOL 1 YL]PROPOXY] 3 METHOXYPHENYL] 5 (3,4 DIMETHOXYPHENYL)PENTA 1,4 DIEN 3 ONE; 4 (2 BROMOETHOXY) 3 METHOXYBENZALDEHYDE; 4 (3 BROMOPROPOXY) 3 METHOXYBENZALDEHYDE; 4 (3,4 DIMETHOXYPHENYL)BUT 3 EN 2 ONE; ANTINEOPLASTIC AGENT; C5 CURCUMINOID; CHLOROQUINE; CURCUMIN; DOXORUBICIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALDOL REACTION; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASYMMETRIC SYNTHESIS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IC 50; NONHUMAN; NUCLEOPHILICITY; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 84893770978     PISSN: 15701808     EISSN: 1875628X     Source Type: Journal    
DOI: 10.2174/15701808113109990061     Document Type: Article

References (48)

1. Kajaria, D. K.; Tripathi, J. S.; Tiwari, S. K. Nebulization therapy - a novel approach to drug delivery system in Ayurveda. Int. Res. J. Pharma., 2011, 2(11), 18-20.
2. Bagla, P. Piercing the veil of Ayurveda. Science, 2011, 334(6062), 1491.
3. Aggarwal, B. B.; Sundaram, C.; Malani, N.; Ichikawa, H. "Curcumin: the Indian solid gold". Adv. Exp. Med. Bio., 2007, 595, 1-75.
4. Ammon, H. P. T.; Wahl, M. A. Pharmacology of Curcuma longa. Planta Med. 1991, 57(1), 1-7.
5. Araujo, C. A. C.; Leon, L. L. Biological activities of Curcuma longa L. Mem. Inst. Oswaldo Cruz, 2001, 96(5), 723-728.
6. Ahmad, N.; Katiyar, S. K.; Mukhtar, H. In: Oxidants and Antioxidants in Cutaneous Biology; Thiele, J.; Elsner, P. (Eds.); Karger: Basel, 2001; Vol. 29, pp. 128-139.
7. Srimal, R. C.; Dhawan, B. N. Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J. Pharm. Pharmacol. 1973, 25(6), 447-452.
8. Jordan, W. C.; Drew, C. R. Curcumin-a natural herb with anti-HIV activity. J. Natl. Med. Assoc., 1996, 88(6), 333.
9. Kumar, S.; Narain, U.; Tripathi, S.; Misra, K. Syntheses of curcumin bioconjugates and study of their antibacterial activities against ß-lactamase-producing microorganisms. Bioconjug. Chem., 2001, 12(4), 464-469.
10. Reddy, R. C.; Vatsalab, P. G.; Keshamounia, V. G.; Padmanaban, G.; Rangarajan, P. N. Curcumin for malaria therapy. Biochem. Biophys. Res. Commun., 2005, 326(2), 472-474.
11. Aggarwal, B.B.; Bhatt, I.D.; Ichikawa, H.; Ahn, K.S.; Sethi, G.; Sandur, S.K.; Sundaram, C.; Seeram, N.; Shishodia, S. In: Turmeric: The genus Curcuma; Ravindran, P. N.; Babu, K. N.; Sivaraman, K. (Eds.); CRC Press: New York, 2007; Vol. 45, pp.297-368.
12. Goel, A.; Kunnumakkara, A. B.; Aggarwal, B. B. Curcumin as "Curecumin": From kitchen to clinic. Biochem. Pharmacol., 2008, 75(4), 787-809.
13. Hatcher, H.; Planalp, R.; Cho, J.; Torti, F. M.; Torti, S. V. Curcumin: From ancient medicine to current clinical trials. Cell. Mol. Life Sci., 2008, 65(11), 1631-1652.
14. Thangapazham, R. L.; Sharma, A.; Maheshwari, R. K. Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J., 2006, 8(3), E443-E449.
15. Tomita, M.; Kawakami, H.; Uchihara, J. N.; Okudaira, T.; Masuda, M.; Takasu, N.; Matsuda, T.; Ohta, T.; Tanaka, Y.; Ohshiro, K.; Mori, N. Curcumin (diferuloylmethane) inhibits constitutive active NFkappaB, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells. Int. J. Cancer, 2006, 118(3), 765-772.
16. Aggarwal, B. B.; Shishodia, S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol., 2006, 71(10), 1397-1421.
17. Sharma, R. A.; Gescher, A. J.; Steward, W. P. Curcumin: the story so far. Eur. J. Cancer, 2005, 41(13), 1955-1968.
18. Hussain, A. R.; Al-Rasheed, M.; Manogaran, P. S.; Al-Hussein, K. A.; Platanias, L. C.; Al Kuraya, K.; Uddin, S. Curcumin induces apoptosis via inhibition of PI3'-kinase/AKT pathway in acute T cell leukemias. Apoptosis, 2006, 11(2), 245-254.
19. Beevers, C. S.; Li, F.; Liu, L.; Huang, S. Curcumin inhibits the mammalian target of rapamycin mediated signaling pathways in cancer cells. Int. J. Cancer, 2006, 119(4), 757-764.
20. Johnson, S. M.; Gulhati, P.; Arrieta, I.; Wang, X.; Uchida, T.; Gao, T.; Evers, B. M. Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signalling. Anticancer Res., 2009, 29(8), 3185-3190.
21. Squires, M. S.; Hudson, E. A.; Howells, L.; Sale, S.; Houghton, C. E.; Jones, J. L.; Fox, L. H.; Dickens, M.; Prigent, S. A.; Manson, M. M. Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/ protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells. Biochem. Pharmacol. 2003, 65(3), 361-376.
22. Shankar, S.; Chen, Q.; Sarva, K.; Siddiqui, I.; Srivastava, R. K. Curcumin enhances the apoptosis inducing potential of TRAIL in prostate cancer cells: Molecular mechanisms of poptosis, migration and angiogenesis. J. Mol. Signal., 2007, 2, 10.
23. Lev-Ari, S.; Starr, A.; Vexler, A.; Karaush, V.; Loew, V.; Greif, J.; Fenig, E.; Aderka, D.; Ben-Yosef, R. Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity. Anticancer Res., 2006, 26(6B), 4423-4430.
24. Korutla, L.; Kumar, R. Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells. Biochim. Biophys. Acta, 1994, 1224(3), 597-600.
25. Reddy, S.; Rishi, A. K.; Xu, H.; Levi, E.; Sarkar, F. H.; Majumdar, A. P. Mechanisms of curcuminand EGF-receptor related protein (ERRP)-dependent growth inhibition of colon cancer cells. Nutr. Cancer, 2006, 55(2), 185-194.
26. Chendil, D.; Ranga, R. S.; Meigooni, D.; Sathishkumar, S.; Ahmed, M. M. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene, 2004, 23(8), 1599-1607.
27. Wahlstrom, B.; Blennow, G. A study on the fate of curcumin in the rat. Acta Pharmacol. Toxicol., 1978, 43(2), 86-92.
28. Wang, Y.-J.; Pan, M.-H.; Cheng, A.-L.; Lin, L.-I.; Ho, Y.-S.; Hsieh, C.-Y.; Lin, J.-K. Stability of curcumin in buffer solutions and characterization of its degradation products. J. Pharm. Biomed. Anal., 1997, 15(12), 1867-1876.
29. Toennesen, H. H.; Karlsen, J. Studies on curcumin and curcuminoids. V. Alkaline degradation of curcumin. Z. Lebensm. Unters. Forsch., 1985, 180(2), 132-134.
30. Rosemond, M. J. C.; St. John-Williams, L.; Yamaguchi, T.; Fujishita, T.; Walsh, J. S. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases. Chem. Biol. Interact., 2004, 147(2), 129-139.
31. Markaverich, B. M.; Schauweker, T. H.; Gregory, R. R.; Varma, M.; Kittrell, F. S.; Medina, D.; Varma, R. S. Nuclear type II sites and malignant cell proliferation: inhibition by 2,6- bisbenzylidenecyclohexanones. Cancer Res., 1992, 52(9), 2482-2488.
32. Artico, M.; Di Santo, R.; Costi, R.; Novellino, E.; Greco, G.; Massa, S.; Tramontano, E.; Marongiu, M. E.; De Montis, A.; La Colla, P. Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of hiv-1 integrase: synthesis, biological evaluation, and molecular modeling. J. Med. Chem., 1998, 41(21),3948-3960.
33. El-Subbagh, H. I.; Abu-Zaid, S. M.; Mahran, M. A.; Badria, F. A.; Al-Obaid, A. M. Synthesis and biological evaluation of certain α,β- unsaturated ketones and their corresponding fused pyridines as antiviral and cytotoxic agents. J. Med. Chem., 2000, 43(15), 2915-2921.
34. Yadav, B.; Taurin, S.; Rosengren, R. J.; Schumacher, M.; Diederich, M.; Somers- Edgar, T. J.; Larsen, L. Synthesis and cytotoxic potential of heterocyclic cyclohexanone analogues of curcumin. Bioorg. Med. Chem., 2010, 18(18), 6701-6707.
35. Das, U.; Sharma, R. K.; Dimmock, J. R.; 1,5-diaryl-3-oxo-1,4-pentadienes: a case for antineoplastics with multiple targets. Curr. Med. Chem., 2009, 16(16), 2001-2020.
36. Adams, B. K.; Ferstl, E. M.; Davis, M. C.; Herold, M.; Kurtkaya, S.; Camalier, R. F.; Hollingshead, M. G.; Kaur, G.; Sausville, E. A.; Rickles, F. R.; Snyder, J. P.; Liotta, D. C.; Shoji, M. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg. Med. Chem., 2004, 12(14), 3871-3883.
37. Katsori, A.-M.; Chatzopoulou, M.; Dimas, K.; Kontogiorgis, C.; Patsilinakos, A.; Trangas, T.; Hadjipavlou-Litina, D. Curcumin analogues as possible anti-proliferative & anti-inflammatory agents. Eur. J. Med. Chem., 2011, 46(7), 2722-2735.
38. Manohar, S.; Khan, S. I.; Kandi, S. K.; Raj, K.; Sun, G.; Yang, X.; Molina, A. D. C.; Ni, N.; Wangc, B.; Rawat, D. S. Synthesis, antimalarial activity and cytotoxic potential of new monocarbonyl analogues of curcumin. Bioorg. Med. Chem., 2013, 23(1), 112-116.
39. Yamakoshi, H.; Ohori, H.; Kudo, C.; Sato, A.; Kanoh, N.; Ishioka,C.; Shibata, H.; Iwabuchi, Y. Structure-activity relationship of C5- curcuminoids and synthesis of their molecular probes thereof. Bioorg. Med. Chem., 2010, 18(3), 1083-1092.
40. Manohar, S.; Khan, S. I.; Rawat, D. S. Synthesis, antimalarial activity and cytotoxicity of 4-aminoquinoline-triazine conjugates. Bioorg. Med. Chem. Lett., 2010, 20(1), 322-325.
41. Manohar, S.; Khan, S. I.; Rawat, D. S. Synthesis of 4- aminoquinoline-1,2,3-triazole and 4-aminoquinoline-1,2,3-triazole- 1,3,5-triazine hybrids as potential antimalarial agents. Chem. Biol. Drug Des., 2011, 78(1), 124-136.
42. Manohar, S.; Rajesh, U. C.; Khan, S. I.; Tekwani, B. L.; Rawat, D. S. Novel 4-aminoquinoline-pyrimidine based hybrids with improved in vitro and in vivo antimalarial activity. ACS. Med. Chem. Lett., 2012, 3(7), 555-559.
43. Manohar, S.; Khan, S. I.; Rawat, D. S. 4-Aminoquinoline-triazinebased hybrids with improved in vitro antimalarial activity against CQ-sensitive and CQ-resistant strains of plasmodium falciparum. Chem. Biol. Drug Des., 2013, 81(5), 625-630.
44. Tatsuzaki, J.; Bastow, K. F.; Nakagawa-Goto, K.; Nakamura, S.; Itokawa, H.; Lee, K.-H. Dehydrozingerone, chalcone, and isoeugenol analogues as in vitro anticancer agents. J. Nat. Prod., 2006, 69(10), 1445-1449.
45. Ryu, E. K.; Choe, Y. S.; Lee, K.-H.; Choi, Y. Kim, B.-T. Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for β-amyloid plaque imaging. J. Med. Chem., 2006, 49(20), 6111-6119.
46. Jain, M.; Khan, S. I.; Tekwani, B. L.; Jacob, M. R.; Singh, S.; Singh, P. P.; Jain R. Synthesis, antimalarial, antileishmanial, and antimicrobial activities of some 8-quinolinamine analogues. Bioorg. Med. Chem., 2005, 13(14), 4458-4466.
47. Makler, M. T.; Hinrichs, D. J. Measurement of the lactate dehydrogenase activity of Plasmodium falciparum as an assessment of parasitemia. Am. J. Trop. Med. Hyg., 1993, 48(2), 205-210.
48. Mustafa, J.; Khan, S. I.; Ma, G.; Walker, L. A.; Khan, I. A. Synthesis and anticancer activities of fatty acid analogs of Podophyllotoxin. Lipids, 2004, 39(2), 167-172.